{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:57:31Z","timestamp":1785211051256,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patient reported outcomes regarding perianal disease and faecal incontinence in the community\u2010based inflammatory bowel disease population are poorly described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To determine the impacts of perianal disease and faecal incontinence on quality of life and employment in inflammatory bowel disease patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For this cross\u2010sectional study, a comprehensive survey was sent out to members of the Dutch National Crohn's and Colitis patient organisation. Validated questionnaires regarding faecal incontinence and active perianal disease were used to estimate its prevalence's. The effect on the quality of life (36\u2010Item Short Form Survey) and on employment status (multivariate binary regression analysis) was assessed in this inflammatory bowel disease population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total number of 1092 returned questionnaires (58% responders) were used for analysis; 750 respondents (69%) were female; mean age was 47 years (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 35\u201059). In 621 patients (57%) Crohn's disease, in 422 (39%) ulcerative colitis and in 49 (4%) patients unclassifiable inflammatory bowel disease was self\u2010reported. The 114 patients (10%) with a stoma were excluded for continence related analyses. Faecal incontinence was reported in 555 patients (57%), was comparable between the different inflammatory bowel disease diagnoses and affected all 36\u2010Item Short Form Survey subscales adversely (incontinence vs continence: Physical functioning 75 vs 84, <jats:italic>P<\/jats:italic> &lt; 0.0001; Limitations due to physical health 49 vs 63, <jats:italic>P<\/jats:italic> &lt; 0.0001; Limitations due to emotional problems 49 vs 64, <jats:italic>P<\/jats:italic> &lt; 0.0001; Energy\/fatigue 47 vs 53, <jats:italic>P<\/jats:italic> &lt; 0.0001; Emotional well\u2010being 71 vs 74, <jats:italic>P<\/jats:italic> = 0.005; Social functioning 63 vs 73, <jats:italic>P<\/jats:italic> &lt; 0.0001; Pain 66 vs 75, <jats:italic>P<\/jats:italic> &lt; 0.0001; General health 41 vs 48, <jats:italic>P<\/jats:italic> &lt; 0.0001). Active perianal disease was reported in 39% Crohn's disease, 16% ulcerative colitis (84% fissures) and 20% unclassifiable inflammatory bowel disease patients. Faecal incontinence was more common in patients with perianal disease (67% vs 53%, <jats:italic>P<\/jats:italic> = 0.003). When correcting for age, disease duration, inflammatory bowel disease\u2010related surgery and faecal incontinence, active perianal disease was independently affecting employment (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> 0.67; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.50\u20130.91; <jats:italic>P<\/jats:italic> = 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Faecal incontinence and perianal disease are quality of life determining factors. Faecal incontinence needs more attention among clinicians, and development of new (drug) therapies needs to be focussed on perianal disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14599","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T07:26:38Z","timestamp":1520580398000},"page":"1253-1260","source":"Crossref","is-referenced-by-count":62,"title":["Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3158-6652","authenticated-orcid":false,"given":"P. F.","family":"Vollebregt","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"van Bodegraven","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology VU University Medical Centre Amsterdam The Netherlands"},{"name":"Department of Gastroenterology, Geriatrics, Internal Medicine and Intensive Care Medicine (Co\u2010MIK) Zuyderland Medical Centre Heerlen\u2010Geleen\u2010Sittard The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M. L.","family":"Markus\u2010de Kwaadsteniet","sequence":"additional","affiliation":[{"name":"Dutch Crohn's and Colitis organisation (CCUVN) Woerden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van der Horst","sequence":"additional","affiliation":[{"name":"Dutch Crohn's and Colitis organisation (CCUVN) Woerden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. F.","family":"Felt\u2010Bersma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303376"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"e0142481","DOI":"10.1371\/journal.pone.0142481","article-title":"Evolution of costs of inflammatory bowel disease over two years of follow\u2010up","volume":"11","author":"Valk ME","year":"2016","journal-title":"PLoS ONE"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.03.005"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2007.06.005"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03877.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001056"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00341234"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v7.i3.447"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000000812"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.11.004"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.01.018"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02212.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2003.08.025"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-014-1926-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0b013e31825228b0"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32362"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e3182099d9e"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2011.02613.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199501000-00008"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.1.77"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.160"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02237236"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.09.009"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1988.10478722"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.009"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.159251"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.12.020"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02234220"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800750711"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000278"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01444.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14599","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T03:42:59Z","timestamp":1695008579000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/apt.14599"],"URL":"https:\/\/doi.org\/10.1111\/apt.14599","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,9]]}}}